Dr. Saad on Results of Radium-223 Trial in Prostate Cancer

Fred Saad, MD
Published: Thursday, Mar 02, 2017



Fred Saad, MD, professor and chief of Urology, director of Genitourinary Oncology at the University of Montreal Hospital Centers, discusses results of a trial that investigated early use of radium-223 dichloride (Xofigo) in patients with asymptomatic metastatic castration-resistant prostate cancer.

According to Saad, radium-223 should be started very soon after first-line treatment—not when the patient becomes symptomatic. The drug proved to delay symptomatic progression, specifically a significant decrease in symptomatic skeletal events.

Asymptomatic patients were shown to have better overall survival compared with symptomatic patients. This hindrance of symptoms allowed most patients to undergo all 6 cycles of treatment, suggesting that earlier use of radium-223 in the disease course could lead to better outcomes overall.
 


Fred Saad, MD, professor and chief of Urology, director of Genitourinary Oncology at the University of Montreal Hospital Centers, discusses results of a trial that investigated early use of radium-223 dichloride (Xofigo) in patients with asymptomatic metastatic castration-resistant prostate cancer.

According to Saad, radium-223 should be started very soon after first-line treatment—not when the patient becomes symptomatic. The drug proved to delay symptomatic progression, specifically a significant decrease in symptomatic skeletal events.

Asymptomatic patients were shown to have better overall survival compared with symptomatic patients. This hindrance of symptoms allowed most patients to undergo all 6 cycles of treatment, suggesting that earlier use of radium-223 in the disease course could lead to better outcomes overall.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x